{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T07:40:09Z","timestamp":1792395609107,"version":"4.4.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.annonc.2026.10.102","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:08:57Z","timestamp":1792166937000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of camrelizumab plus docetaxel and carboplatin as neoadjuvant therapy for stage II-III triple-negative breast cancer: the HELEN-Trio 011 randomized clinical trial"],"prefix":"10.1016","author":[{"given":"D.","family":"Jiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"L\u00fc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.annonc.2026.10.102_bib1","article-title":"Treatment landscape of triple-negative breast cancer - expanded options, evolving needs","volume":"19","author":"Giampaolo","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"0","key":"10.1016\/j.annonc.2026.10.102_bib2","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Rebecca","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.annonc.2026.10.102_bib3","article-title":"Pembrolizumab for Early Triple-Negative Breast Cancer","volume":"382","author":"Peter","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.annonc.2026.10.102_bib4","article-title":"Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer","volume":"386","author":"Peter","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.annonc.2026.10.102_bib5","article-title":"Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label phase II trial","volume":"150","author":"Liulu","year":"2021","journal-title":"Int J Cancer"},{"issue":"13","key":"10.1016\/j.annonc.2026.10.102_bib6","article-title":"Application of Neoadjuvant Docetaxel plus Cisplatin in Early-Stage Triple-Negative Breast Cancer (HELEN-001): Results from a Phase II Trial","volume":"31","author":"Dechuang","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.annonc.2026.10.102_bib7","article-title":"Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I-III Triple-negative Breast Cancer (NeoSTOP)","volume":"27","author":"Priyanka","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.annonc.2026.10.102_bib8","article-title":"Platinum is essential in neoadjuvant treatment of triple-negative breast cancer: a network meta-analysis","volume":"19","author":"Junjie","year":"2022","journal-title":"Cancer Biol Med"},{"issue":"2","key":"10.1016\/j.annonc.2026.10.102_bib9","article-title":"Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial","volume":"10","author":"Priyanka","year":"2023","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2026.10.102_bib10","article-title":"Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study","volume":"21","author":"Jing","year":"2020","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2026.10.102_bib11","article-title":"Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial","volume":"326","author":"Huiyan","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.annonc.2026.10.102_bib12","article-title":"Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer","volume":"13","author":"Jieqiong","year":"2022","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.annonc.2026.10.102_bib13","article-title":"Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial","volume":"21","author":"Shukui","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.10.102_bib14","article-title":"Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin in early triple-negative breast cancer: a single-arm phase II trial","volume":"14","author":"Chengzheng","year":"2023","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.annonc.2026.10.102_bib15","article-title":"Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial","volume":"333","author":"Li","year":"2024","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.annonc.2026.10.102_bib16","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/PAI.0000000000001223","article-title":"Concordance of PD-L1 Expression in Metastatic Triple-negative Breast Cancer Between the 22C3 and E1L3N Antibodies Using Combined Positive Scoring","volume":"32","author":"Erick","year":"2024","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"1","key":"10.1016\/j.annonc.2026.10.102_bib17","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41523-022-00500-3","article-title":"A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013","volume":"8","author":"Ademuyiwa","year":"2022","journal-title":"NPJ Breast Cancer"},{"issue":"3","key":"10.1016\/j.annonc.2026.10.102_bib18","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S1470-2045(24)00757-5","article-title":"Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902\/IBCSG 61-20; Neo-N): a non-comparative, open-label, randomised, phase 2 trial","volume":"26","author":"Zdenkowski","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2026.10.102_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103709","article-title":"Neoadjuvant tislelizumab plus nab-paclitaxel and carboplatin for triple-negative breast cancer: a multicenter, open-label, phase II cTRIO study","volume":"91","author":"Wang","year":"2026","journal-title":"EClinicalMedicine"},{"issue":"10257","key":"10.1016\/j.annonc.2026.10.102_bib20","article-title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial","volume":"396","author":"Elizabeth","year":"2020","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.annonc.2026.10.102_bib21","article-title":"A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study","volume":"30","author":"S","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.10.102_bib22","unstructured":"Sibylle L, Michael U, Jens H et al. Durvalumab in Combination With Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: Long-Term Analysis From the GeparNuevo Trial. J Clin Oncol 2026 (0)."},{"issue":"13","key":"10.1016\/j.annonc.2026.10.102_bib23","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1158\/1078-0432.CCR-24-3435","article-title":"Global Transcriptional Complexity of Estrogen Receptor-Low Positive Breast Cancers in the Prospective Swedish Population-Based SCAN-B Cohort","volume":"31","author":"Kimbung","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"16","key":"10.1016\/j.annonc.2026.10.102_bib24","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1200\/JCO-24-02263","article-title":"Endocrine Therapy Omission in Estrogen Receptor-Low (1%-10%) Early-Stage Breast Cancer","volume":"43","author":"Choong","year":"2025","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2026.10.102_bib25","article-title":"Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial","volume":"25","author":"Leonie","year":"2019","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.annonc.2026.10.102_bib26","article-title":"Combining DNA damaging therapeutics with immunotherapy: more haste, less speed","volume":"118","author":"Jessica","year":"2017","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.annonc.2026.10.102_bib27","article-title":"Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial","volume":"31","author":"Elizabeth","year":"2025","journal-title":"Nat Med"},{"issue":"13","key":"10.1016\/j.annonc.2026.10.102_bib28","article-title":"Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA\/IMpassion030 Randomized Clinical Trial","volume":"333","author":"Michail","year":"2025","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.annonc.2026.10.102_bib29","article-title":"Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study","volume":"33","author":"L","year":"2022","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2026.10.102_bib30","article-title":"Contrasting effects of cyclophosphamide on anti-CTL-associated protein 4 blockade therapy in two mouse tumor models","volume":"108","author":"Yuichi","year":"2017","journal-title":"Cancer Sci"},{"issue":"2","key":"10.1016\/j.annonc.2026.10.102_bib31","article-title":"Impact of the combined timing of PD-1\/PD-L1 inhibitors and chemotherapy on the outcomes in patients with refractory lung cancer","volume":"6","author":"W","year":"2021","journal-title":"ESMO Open"},{"issue":"8","key":"10.1016\/j.annonc.2026.10.102_bib32","article-title":"5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity","volume":"70","author":"Julie","year":"2010","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.annonc.2026.10.102_bib33","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41591-019-0432-4","article-title":"Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial","volume":"25","author":"Voorwerk","year":"2019","journal-title":"Nat Med"},{"issue":"0","key":"10.1016\/j.annonc.2026.10.102_bib34","article-title":"The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer-A Phase II Study","volume":"12","author":"Wenqun","year":"2021","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.annonc.2026.10.102_bib35","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/jnci\/djab004","article-title":"Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study","volume":"113","author":"Emens","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"10265","key":"10.1016\/j.annonc.2026.10.102_bib36","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2026.10.102_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102257","article-title":"Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis","volume":"99","author":"Boman","year":"2021","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"10.1016\/j.annonc.2026.10.102_bib38","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/1750743X.2025.2500908","article-title":"The complexities of PD-L1 expression as an indicator of immunotherapy outcomes","volume":"17","author":"Needleman","year":"2025","journal-title":"Immunotherapy"},{"issue":"7","key":"10.1016\/j.annonc.2026.10.102_bib39","article-title":"The complexities of PD-L1 expression as an indicator of immunotherapy outcomes","volume":"17","author":"Robert","year":"2025","journal-title":"Immunotherapy"},{"issue":"2","key":"10.1016\/j.annonc.2026.10.102_bib40","article-title":"Cancer cell death: Cell-autonomous and immunogenic dimensions","volume":"44","author":"Lorenzo","year":"2026","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.annonc.2026.10.102_bib41","article-title":"Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo","volume":"31","author":"T","year":"2020","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.10.102_bib42","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13045-020-00886-2","article-title":"Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial","volume":"13","author":"Wang","year":"2020","journal-title":"J Hematol Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426068845?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426068845?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T06:48:15Z","timestamp":1792392495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753426068845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":42,"alternative-id":["S0923753426068845"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2026.10.102","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of camrelizumab plus docetaxel and carboplatin as neoadjuvant therapy for stage II-III triple-negative breast cancer: the HELEN-Trio 011 randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2026.10.102","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society for Medical Oncology. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}